Travis LeGuyader


Recent posts by Travis LeGuyader

1 min read

Hey, Boston & Cambridge!  We're hosting a free happy hour!

By Travis LeGuyader on 2/12/20 7:30 AM

Updated 3/6/20: Event cancelled due to concerns surrounding spread of COVID-19 virus. 

A note from the event organizers:

Thank you for your interest in our event, and we apologize that we must postpone the happy hour indefinitely due to concerns surrounding the spread of Covid-19 infection. 

We're proud to announce that we had over 100 attendees registered a week ahead of the event. When the time is right, we will announce a revised event date. 

Sincerely,

Ryan, Travis, Lisa, Marcus & Morgan

Thursday | March 12 | 5:00-7:30 PM | Cambridge, MA

Open Bar & Free Appetizers

 

LIMITED SPACE, REGISTER NOW FOR FREE

What is Brews & Biopharma?

A free happy hour for biopharma scientists.

An exclusive, relaxed event for biopharma scientists in the protein sciences.

Finish your workday (and start your night) with us over casual drinks, appetizers, and networking.

Who is invited?

Scientists from our partner companies and their invited guests*

Just forward this invitation to them &

tell them to list you as their host while registering.

REGISTER FOR FREE TODAY

 

*We kindly ask you not to invite your professional recruiter or salesperson friends as your guests.

Nobody likes to be pitched after work. Thank you for respecting our policy. 

Topics: Insider Events
1 min read

COO of Abveris, Tracey Mullen, to Present at Antibody Engineering 2019 in San Diego

By Travis LeGuyader on 12/3/19 1:49 PM

December 9, 2019 – San Diego, CA - Are you attending the upcoming Antibody Engineering and Therapeutics conference in San Diego on December 9th? It’s not too late to sign up and spend some time in the sun while staying updated on the latest antibody discovery technologies and engineering techniques while networking with lead scientists in the antibody discovery world.

Join us on December 12 at noon for a scientific briefing led by Tracey Mullen, our Chief Operating Officer. Or, stop by our booth or posters in the exhibit hall and meet with Garren (CEO), Ryan (Director of Business Development) and Travis (Business Development Associate). See you there!

Click here to schedule an appointment with our team at the conference.

Information on our Scientific Briefing:

Scientific Briefing: Antibody Discovery for Traditionally Difficult Targets: in vivo, in vitro, or both?

Abstract: Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional techniques typically fail to produce a productive response in situations where, for example, the target epitope has poor immunogenicity or is a rare, cryptic site. While some in vitro platforms can overcome these difficulties through careful guiding selection methods, significant downstream engineering is often required to ensure lead candidates harbor appropriate development qualities. Fortunately, recent advancements in protein engineering and antibody discovery have enabled improved drug development to these traditionally difficult targets. Using the AbX platform, the power of the immune system is harnessed to exemplify the breadth and comprehensive nature of the B cell repertoire. When applied to the most difficult target classes, lead candidates can be uncovered where traditional in vivo platforms typically fail, or significant engineering is required for in vitro discovery.

About the Antibody Engineering Conference: Antibody Engineering is the #1 antibody engineering conference for accelerating next-generation antibodies to commercial success. Find the latest science, technology, and partners in antibody engineering, immunobiology, and next-generation binders.

 

Antibody Engineering Logo

 

Topics: Conferences
1 min read

WEBINAR: Excellence In Anti-Idiotype Antibody Discovery

By Travis LeGuyader on 10/28/19 6:29 PM

Date: November 13, 2019 at 2PM ET (11AM PT)

TraceyMullenPlease join Abveris' Chief Operating Officer, Tracey Mullen, for our webinar to learn more about our premier anti-idiotype antibody discovery service for mAbs, bispecifics, scFvs, VHHs, and more.

Benefits of our approach:
  • Rapid reagent generation timelines
  • Maximal epitope coverage with DiversimAb technology
  • Highly sensitive specificity screening
  • Identification of high-affinity mAbs
  • Neutralizing and non-neutralizing mAbs
  • Flexible deliverable strategies
  • All work done in the USA

Abveris has the expertise and technology advantages required to develop high-quality reagents to the trickiest biotherapeutic molecules. Join our webinar to learn more.

Interested, but have a scheduling conflict? Click here to register and a video link will be sent after the webinar finishes. 


Click Here to register Nov. 13th at 2PM EST (11AM PST) .    Click Here to view our anti-idiotype package pricing

Topics: Insider Service & Product Updates
1 min read

Abveris and Geneious Biologics Collaborate to Advance Antibody NGS Data Analysis

By Travis LeGuyader on 8/12/19 8:01 AM

Canton, MA, USA – August 12, 2019 – Boston-based antibody discovery services company Abveris has partnered with Biomatters to incorporate the Geneious Biologics data analysis platform into their antibody discovery workflow. In collaboration, a new Single Clone Antibody Annotator pipeline has been developed.

With a rapidly growing customer base and a wide range of antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as a premium hub for bioinformatics and computer programming capabilities.

"The Geneious team has done an excellent job accommodating our specific data resulting in a streamlined, high-throughput workflow that produces accurate data and operates efficiently without the need to integrate multiple bioinformatics platforms," remarked Dr. Colby Souders, Chief Technology Officer at Abveris. "We look forward to continuously improving the platform and its integration into our workflow to combine sequence analytics with metadata and assay data to accelerate candidate selection."

The Geneious team worked closely with Abveris to optimize and enhance the handling of their antibody NGS data. Jannick Bendtsen, VP Technology Services at Geneious, commented, "Abveris is at the cutting edge of antibody drug discovery; they are pushing the boundaries of science and technology. To have Colby and the team select Geneious Biologics is a great honor and a great compliment. We collaborated to integrate our Single Clone Antibody Annotator Pipeline, and it now runs out of the box. It's all about speed and accuracy in the discovery process."

About Abveris: Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at https://www.abveris.com.

About Geneious and Biomatters: Biomatters empowers its customers with software that transforms biological data into knowledge and actionable insights across the spectrum of biotechnology research and development, including drug discovery, protein engineering, and advanced comparative analysis of DNA, RNA, and protein sequences. Geneious solutions are created from a deep understanding of customer experience to turn the difficult into the intuitive and easy. Geneious is trusted by over 4,000 companies, universities, and institutes all over the globe. Additional information about Geneious is available at https://www.geneious.com.

Topics: Press Releases Service & Product Updates

Featured